サマリー

2030年までの欧米脊髄腫瘍転移市場調査レポート予測

市場概要
米国と欧州の転移性脊髄腫瘍市場の成長は、転移性脊髄腫瘍の罹患率の増加と研究スタートアッププログラムの立ち上げに起因している。しかし、脊椎腫瘍治療に伴う副作用が市場成長の妨げになると予想される。
転移性脊髄腫瘍は、脊椎や脊髄に隣接して発生する異常な組織塊である。転移性脊椎腫瘍の95％以上は硬膜外または椎体内で発見され、50％以上は脊椎の複数レベルで発見される。これらのタイプのがんは、続発性脊髄腫瘍または脊髄転移とも呼ばれます。さらに、原発性脊髄腫瘍は脊柱から始まる腫瘍です。これらは非常にまれで、ほとんどが良性（非がん性）であり、脊髄腫瘍のごく一部を占めている。
転移性脊髄腫瘍の罹患率の増加と研究開始プログラムの立ち上げは、米国と欧州の転移性脊髄腫瘍市場の成長を促進する重要な要因である。しかし、脊椎腫瘍治療に伴う副作用が米国と欧州の転移性脊椎腫瘍市場の成長を抑制している。とはいえ、進行中の臨床試験は、米国と欧州の転移性脊髄腫瘍市場で活動するプレーヤーにとって有利な機会を生み出すと予想される。
市場区分
タイプ別に、米国と欧州の転移性脊髄腫瘍市場は、硬膜外、硬膜内-髄外、髄内に区分される。
診断と治療に基づき、米国と欧州の転移性脊髄腫瘍市場は診断と治療に区分される。2022年は治療セグメントが市場を支配し、2023-2030年の予測期間中は診断セグメントが最も急成長すると予測されている。
エンドユーザーに基づき、米国と欧州の転移性脊髄腫瘍市場は、病院＆クリニック、外来手術センター、研究＆学術機関、その他にセグメント化された。
欧州の転移性脊髄腫瘍市場は2022年に51.32%の市場シェアで最大市場を占め、予測期間中は米国が最も急成長すると予測される。
主要プレイヤー
GE Healthcare（米国）、Medtronic Plc（アイルランド）、Amgen Inc（米国）、Siemens Healthineers AG（ドイツ）、Stryker（米国）、Merit Medical Systems（米国）、Brainlab AG（ドイツ）、Johnson & Johnson Services Inc（米国）、Zimmer Biomet（米国）、島津製作所（日本）。

ページTOPに戻る

目次

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
1.1 OVERVIEW 13
2 MARKET INTRODUCTION 14
2.1 DEFINITION 14
2.2 SCOPE OF THE STUDY 14
2.3 RESEARCH OBJECTIVE 14
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 15
3 RESEARCH METHODOLOGY 16
3.1 DATA MINING 16
3.2 SECONDARY RESEARCH 17
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 19
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 20
3.6.1 BOTTOM-UP APPROACH 21
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS 24
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 INCREASING INCIDENCES OF METASTASES SPINAL TUMOR 25
4.2.2 LAUNCH OF THE RESEARCH START-UP PROGRAMME 25
4.3 RESTRAINTS 26
4.3.1 SIDE EFFECTS ASSOCIATED WITH SPINE TUMOR TREATMENTS 26
4.4 OPPORTUNITIES 26
4.4.1 ONGOING CLINICAL TRIALS 26
4.4.2 LAUNCH OF RESEARCH CENTRES AND SUPPORT FOR RESEARCH FUNDING 27
5 MARKET FACTOR ANALYSIS 28
5.1 VALUE CHAIN ANALYSIS 28
5.1.1 R&D 29
5.1.2 MANUFACTURING 29
5.1.3 DISTRIBUTION & SALES 29
5.1.4 POST-SALES MONITORING 29
5.2 PORTER'S FIVE FORCES MODEL 30
5.2.1 THREAT OF NEW ENTRANTS 30
5.2.2 BARGAINING POWER OF SUPPLIERS 31
5.2.3 THREAT OF SUBSTITUTES 31
5.2.4 BARGAINING POWER OF BUYERS 31
5.2.5 INTENSITY OF RIVALRY 31
5.3 IMPACT OF COVID-19 ON THE US AND EUROPE METASTASES SPINAL TUMOR MARKET 32
5.3.1 IMPACT ON SUPPLY CHAIN 32
5.3.2 IMPACT ON MARKET PLAYERS 32
6 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY TYPE 33
6.1 OVERVIEW 33
6.2 EXTRADURAL 35
6.3 INTRADURAL-EXTRAMEDULLARY 36
6.4 INTRAMEDULLARY 36
7 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT 37
7.1 OVERVIEW 37
7.2 DIAGNOSIS 39
7.2.1 IMAGING TESTS 40
7.2.1.1 X-RAY 40
7.2.1.2 COMPUTED TOMOGRAPHY (CT SCAN) 41
7.2.1.3 MAGNETIC RESONANCE IMAGING (MRI SCAN) 41
7.2.1.4 ANGIOGRAPHY 41
7.2.1.5 F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY 42
7.2.1.6 OTHERS 42
7.2.2 BIOPSY 42
7.2.3 OTHERS 43
7.3 TREATMENT 43
7.3.1 NON OPERATIVE TREATMENT 44
7.3.1.1 MEDICATIONS 44
7.3.1.2 RADIATION THERAPY 45
7.3.1.3 ABLATION 45
7.3.1.4 CHEMOTHERAPY 45
7.3.2 SURGICAL TREATMENT 46
7.3.2.1 MINIMALLY INVASIVE SURGERY 46
7.3.2.2 OPEN SURGERY 47
8 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY END USER 48
8.1 OVERVIEW 48
8.2 HOSPITAL AND CLINICS 50
8.3 AMBULATORY SURGERY CENTERS 51
8.4 RESEARCH & ACADEMIC INSTITUTES 51
8.5 OTHERS 51
9 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY REGION/COUNTRY 52
9.1 OVERVIEW 52
9.2 US 54
9.3 EUROPE 57
9.3.1 GERMANY 62
9.3.2 FRANCE 64
9.3.3 UK 67
9.3.4 ITALY 70
9.3.5 SPAIN 72
9.3.6 REST OF EUROPE 75
10 COMPETITIVE LANDSCAPE 78
10.1 OVERVIEW 78
10.2 COMPETITIVE BENCHMARKING 79
10.3 MAJOR GROWTH STRATEGY IN THE US AND EUROPE METASTASES SPINAL TUMOR MARKET 80
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE US AND EUROPE METASTASES SPINAL TUMOR MARKET 80
10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 81
10.5.1 PRODUCT APPROVAL AND PRODUCT LAUNCH 81
10.6 MAJOR PLAYERS SALES ANALYSIS 81
10.6.1 SALES 81
10.6.2 MAJOR PLAYERS R&D ANALYSIS 82
11 COMPANY PROFILES 83
11.1 GE HEALTHCARE 83
11.1.1 COMPANY OVERVIEW 83
11.1.2 FINANCIAL OVERVIEW 84
11.1.3 PRODUCTS OFFERED 84
11.1.4 KEY DEVELOPMENTS 85
11.1.5 SWOT ANALYSIS 85
11.1.6 KEY STRATEGIES 85
11.2 SIEMENS HEALTHINEERS AG 86
11.2.1 COMPANY OVERVIEW 86
11.2.2 FINANCIAL OVERVIEW 87
11.2.3 PRODUCTS OFFERED 87
11.2.4 KEY DEVELOPMENTS 88
11.2.5 KEY STRATEGIES 88
11.3 SHIMADZU CORPORATION 89
11.3.1 COMPANY OVERVIEWS 89
11.3.2 FINANCIAL OVERVIEW 90
11.3.3 PRODUCTS OFFERED 90
11.3.4 KEY DEVELOPMENTS 91
11.3.5 KEY STRATEGIES 91
11.4 ZIMMER BIOMET 92
11.4.1 COMPANY OVERVIEW 92
11.4.2 FINANCIAL OVERVIEW 93
11.4.3 PRODUCTS OFFERED 93
11.4.4 KEY DEVELOPMENTS 94
11.4.5 SWOT ANALYSIS 94
11.4.6 KEY STRATEGIES 94
11.5 JOHNSON & JOHNSON SERVICES, INC 95
11.5.1 COMPANY OVERVIEW 95
11.5.2 FINANCIAL OVERVIEW 96
11.5.3 PRODUCTS OFFERED 96
11.5.4 KEY DEVELOPMENTS 97
11.5.5 KEY STRATEGIES 97
11.6 MERIT MEDICAL SYSTEMS 98
11.6.1 COMPANY OVERVIEW 98
11.6.2 FINANCIAL OVERVIEW 99
11.6.3 PRODUCTS OFFERED 99
11.6.4 KEY DEVELOPMENTS 100
11.6.5 SWOT ANALYSIS 100
11.6.6 KEY STRATEGIES 100
11.7 AMGEN INC. 101
11.7.1 COMPANY OVERVIEW 101
11.7.2 FINANCIAL OVERVIEW 102
11.7.3 PRODUCTS OFFERED 102
11.7.4 KEY DEVELOPMENTS 103
11.7.5 KEY STRATEGIES 103
11.8 STRYKER 104
11.8.1 COMPANY OVERVIEW 104
11.8.2 FINANCIAL OVERVIEW 105
11.8.3 PRODUCTS OFFERED 106
11.8.4 KEY DEVELOPMENTS 106
11.8.5 SWOT ANALYSIS 107
11.8.6 KEY STRATEGIES 107
11.9 MEDTRONIC PLC 108
11.9.1 COMPANY OVERVIEW 108
11.9.2 FINANCIAL OVERVIEW 109
11.9.3 PRODUCTS OFFERED 109
11.9.4 KEY DEVELOPMENTS 110
11.9.5 SWOT ANALYSIS 110
11.9.6 KEY STRATEGIES 110
11.10 BRAINLAB AG 111
11.10.1 COMPANY OVERVIEW 111
11.10.2 FINANCIAL OVERVIEW 111
11.10.3 PRODUCTS OFFERED 111
11.10.4 KEY DEVELOPMENTS 111
11.10.5 KEY STRATEGIES 111
12 APPENDIX 112
12.1 REFERENCES 112
12.2 RELATED REPORTS 113

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 15
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
TABLE 3 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030(USD MILLION) 35
TABLE 4 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR EXTRADURAL, BY REGION/COUNTRY, 2019–2030(USD MILLION) 35
TABLE 5 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR INTRADURAL-EXTRAMEDULLARY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 36
TABLE 6 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR INTRAMEDULLARY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 36
TABLE 7 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030(USD MILLION) 38
TABLE 8 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 39
TABLE 9 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030(USD MILLION) 39
TABLE 10 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 40
TABLE 11 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030(USD MILLION) 40
TABLE 12 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR X-RAY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 40
TABLE 13 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR COMPUTED TOMOGRAPHY (CT SCAN), BY REGION/COUNTRY, 2019–2030(USD MILLION) 41
TABLE 14 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR MAGNETIC RESONANCE IMAGING (MRI SCAN), BY REGION/COUNTRY, 2019–2030(USD MILLION) 41
TABLE 15 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR ANGIOGRAPHY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 41
TABLE 16 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 42
TABLE 17 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR OTHERS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 42
TABLE 18 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR BIOPSY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 42
TABLE 19 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR OTHERS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 43
TABLE 20 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY REGION/COUNTRY, 2019–2030(USD MILLION) 43
TABLE 21 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030(USD MILLION) 43
TABLE 22 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR NON OPERATIVE TREATMENT, BY REGION/COUNTRY, 2019–2030(USD MILLION) 44
TABLE 23 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR NON OPERATIVE TREATMENT, BY TYPE, 2019–2030(USD MILLION) 44
TABLE 24 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR MEDICATIONS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 44
TABLE 25 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR RADIATION THERAPY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 45
TABLE 26 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR ABLATION, BY REGION/COUNTRY, 2019–2030(USD MILLION) 45
TABLE 27 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR CHEMOTHERAPY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 45
TABLE 28 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY REGION/COUNTRY, 2019–2030(USD MILLION) 46
TABLE 29 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030(USD MILLION) 46
TABLE 30 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR MINIMALLY INVASIVE SURGERY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 46
TABLE 31 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR OPEN SURGERY, BY REGION/COUNTRY, 2019–2030(USD MILLION) 47
TABLE 32 US AND EUROPE METASTASES SPINAL TUMOR MARKET, BY END USER 2019–2030(USD MILLION) 50
TABLE 33 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR HOSPITAL AND CLINICS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 50
TABLE 34 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR AMBULATORY SURGERY CENTERS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 51
TABLE 35 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION/COUNTRY, 2019–2030(USD MILLION) 51
TABLE 36 US AND EUROPE METASTASES SPINAL TUMOR MARKET, FOR OTHERS, BY REGION/COUNTRY, 2019–2030(USD MILLION) 51
TABLE 37 US & EUROPE: METASTASES SPINAL TUMOR MARKET, BY REGION/COUNTRY, 2019–2030 (USD MILLION) 53
TABLE 38 US: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 54
TABLE 39 US: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 55
TABLE 40 US: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 55
TABLE 41 US: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 55
TABLE 42 US: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 56
TABLE 43 US: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 56
TABLE 44 US: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 56
TABLE 45 US: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 57
TABLE 46 EUROPE: METASTASES SPINAL TUMOR MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 58
TABLE 47 EUROPE: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 59
TABLE 48 EUROPE: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 59
TABLE 49 EUROPE: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 60
TABLE 50 EUROPE: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 60
TABLE 51 EUROPE: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 60
TABLE 52 EUROPE: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 61
TABLE 53 EUROPE: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 61
TABLE 54 EUROPE: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 61
TABLE 55 GERMANY: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 62
TABLE 56 GERMANY: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 62
TABLE 57 GERMANY: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 62
TABLE 58 GERMANY: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 63
TABLE 59 GERMANY: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 63
TABLE 60 GERMANY: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 63
TABLE 61 GERMANY: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 64
TABLE 62 GERMANY: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 64
TABLE 63 FRANCE: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 64
TABLE 64 FRANCE: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 65
TABLE 65 FRANCE: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 65
TABLE 66 FRANCE: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 65
TABLE 67 FRANCE: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 66
TABLE 68 FRANCE: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 66
TABLE 69 FRANCE: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 66
TABLE 70 FRANCE: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 67
TABLE 71 UK: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 67
TABLE 72 UK: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 67
TABLE 73 UK: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 68
TABLE 74 UK: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 68
TABLE 75 UK: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 68
TABLE 76 UK: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 69
TABLE 77 UK: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 69
TABLE 78 UK: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 69
TABLE 79 ITALY: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 70
TABLE 80 ITALY: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 70
TABLE 81 ITALY: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 70
TABLE 82 ITALY: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 71
TABLE 83 ITALY: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 71
TABLE 84 ITALY: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 71
TABLE 85 ITALY: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 72
TABLE 86 ITALY: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 72
TABLE 87 SPAIN: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 72
TABLE 88 SPAIN: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 73
TABLE 89 SPAIN: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 73
TABLE 90 SPAIN: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 73
TABLE 91 SPAIN: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 74
TABLE 92 SPAIN: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 74
TABLE 93 SPAIN: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 74
TABLE 94 SPAIN: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 75
TABLE 95 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, BY TYPE, 2019–2030 (USD MILLION) 75
TABLE 96 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2019–2030 (USD MILLION) 75
TABLE 97 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2030 (USD MILLION) 76
TABLE 98 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, FOR IMAGING TESTS, BY TYPE, 2019–2030 (USD MILLION) 76
TABLE 99 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, FOR TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 76
TABLE 100 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, FOR NON-OPERATIVE TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 77
TABLE 101 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, FOR SURGICAL TREATMENT, BY TYPE, 2019–2030 (USD MILLION) 77
TABLE 102 REST OF EUROPE: METASTASES SPINAL TUMOR MARKET, BY END USER, 2019–2030 (USD MILLION) 77
TABLE 103 MAJOR PLAYERS IN THE US AND EUROPE METASTASES SPINAL TUMOR MARKET 78
TABLE 104 MOST ACTIVE PLAYER IN THE US AND EUROPE METASTASES SPINAL TUMOR MARKET 80
TABLE 105 PRODUCT APPROVAL AND PRODUCT LAUNCH: US AND EUROPE METASTASES SPINAL TUMOR MARKET 81
TABLE 106 GE HEALTHCARE: PRODUCTS OFFERED 84
TABLE 107 GE HEALTHCARE: KEY DEVELOPMENTS 85
TABLE 108 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 87
TABLE 109 SHIMADZU CORPORATION: PRODUCTS OFFERED 90
TABLE 110 ZIMMER BIOMET: PRODUCTS OFFERED 93
TABLE 111 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED 96
TABLE 112 MERIT MEDICAL SYSTEMS: PRODUCTS OFFERED 99
TABLE 113 AMGEN INC.: PRODUCTS OFFERINGS 102
TABLE 114 STRYKER: PRODUCTS OFFERED 106
TABLE 115 STRYKER: KEY DEVELOPMENTS 106
TABLE 116 MEDTRONIC PLC: PRODUCTS OFFERED 109
TABLE 117 BRAINLAB AG: PRODUCTS OFFERED 111